1. health and fitness

Partnerships, Licensing, Investments and M&A
Deals and Trends for 2015 in Pharmaceuticals
No of Pages – 173
Publishing Date - April 4, 2016
Browse detailed TOC, Tables, Figures, Charts in Partnerships, Licensing, Investments and
M&A Deals and Trends for 2015 in Pharmaceuticals at http://www.marketreportsworld.com/10157403
Summary
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in
Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing,
mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report
provides detailed information on partnership and licensing transactions, M&As, equity/debt
offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2015.
The report portrays detailed comparative data on the number of deals and their value in the last five
years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report
provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals
eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose
throatdisorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders,
hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and
dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's
health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and
venturefinancing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing,
partnerships,licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone
payments,primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five years.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America,
andthe Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key
advisorssuch as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing
agreements;divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments
inthe pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.Evaluate the clinical development stages where majority of the partnerships and licensing
agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and
partnershipsthat have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or
foracquisitions within the industry.
Ask for Discount at – http://www.marketreportsworld.com/enquiry/request-discount/10157403
1 Table of Contents
1 Table of Contents 2 1.1 List of Tables 7
1.2 List of Figures 12
2 Pharmaceutical & Healthcare, Global, Deals Summary 18
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2015 18
2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2015 by Quarter 20
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2015 22
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2015 23
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2015 24
2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2015 25
2.5.1 Allergan and Pfizer to Combine in USD160 Billion Deal 25
2.5.2 Teva Pharma to Acquire Generics Drug Business from Allergan for USD40.5 Billion 26
2.5.3 Actavis Raises USD21 Billion in Public Offering of Senior Notes 27
2.5.4 AbbVie Acquires Pharmacyclics 28
2.5.5 Pfizer Acquires Hospira for USD17 Billion 29
2.5.6 Danaher Acquires Pall for USD13.8 Billion 30
2.5.7 CVS Health Acquires Omnicare for USD12.9 Billion 31
2.5.8 UnitedHealth Acquires Catamaran for USD12.8 Billion 32
2.5.9 Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 32
2.5.10 AbbVie Raises USD16.7 Billion in Public Offering of Notes 34
3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2015 35
4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 36
4.1 Pharmaceuticals & Healthcare, Global, M&A, 2015 36
4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2015 by Quarter 37
4.1.2 Top M&A Deals in 2015 38
4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2015 39
4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2015 40
4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2015 by Quarter 41
4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2015 42
4.2.3 Top IPOs in 2015 43
4.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2015 44
4.2.5 Top Secondary Offerings in 2015 45
4.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2015 45
4.2.7 Top PIPE Deals in 2015 46
4.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2015 47
4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2015 48
4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2015 by Quarter 49
4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2015 50
4.3.3 Top Public Debt Offerings in 2015 51
4.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2015 51
4.3.5 Top Private Debt Placements in 2015 52
4.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2015 53
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2015 54
4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2015 by Quarter 55
4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2015 57
4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone
Paymentsand Deal Value (US$ m), 2015 58
4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront &
Milestone Payments and Deal Values (US$ m), 2015 59
4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2015
60
4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$
m),2015 61
4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone
Payments and Deal Values (US$ m), 2015 63
4.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2015 64
4.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2015 65
4.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2015
65
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2015 66
4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2015 by Quarter 67
4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2015 68
4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone
Payments and Deal Value (US$ m), 2015 69
4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront
&
Milestone Payments and Deal Values (US$ m), 2015 70
4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total
DealValues (US$ m), 2015 71
4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal
Values (US$ m), 2015 72
4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront &
Milestone Payments and Deal Values (US$ m), 2015 74
4.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2015 75
4.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment,
2015 76
4.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone
Payment,2015 77
4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2015 78
4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2015 by Quarter 79
4.6.2 Top Private Equity Deals in 2015 80
4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2015 81
4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2015 82
4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2015 by Quarter 83
4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2015 84
4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2015 85
4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2015 86
4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 87
4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2015 88
4.7.7 Top Venture Financing Deals in 2015 90
5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 91
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2015 91
5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2015 by Quarter 93
5.1.2 Oncology - Deals of the Year 94
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2015 98
5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2015 by Quarter 100
5.2.2 Central Nervous System - Deals of the Year 101
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2015 106
5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2015 by Quarter 108
5.3.2 Infectious Disease - Deals of the Year 109
5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2015 113
5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2015 by Quarter 115
5.4.2 Immunology - Deals of the Year 116
5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2015 119
5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2015 by Quarter 121
5.5.2 Cardiovascular - Deals of the Year 122
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2015 125
5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2015 by Quarter 127
5.6.2 Metabolic Disorders - Deals of the Year 128
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2015 131
5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2015 by Quarter 133
5.7.2 Gastrointestinal - Deals of the Year 134
6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 137
6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2015 137
6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2015 by Quarter 139
6.1.2 North America - Deals of the Year 140
6.2 Pharmaceuticals & Healthcare, European Region Deals, 2015 146
6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2015 by Quarter 148
6.2.2 Europe - Deals of the Year 149
6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2015 154
6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2015 by Quarter 156
6.3.2 Asia-Pacific - Deals of the Year 157
6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2015 160
6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2015 by Quarter 162
6.4.2 Rest of the World - Deals of the Year 163
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 166
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2015 166
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2015 168
8 Further Information 170
8.1 Methodology 170
8.2 About GlobalData 171
8.3 Disclosure information 171
8.4 Disclaimer 172
Report Details –
Date of Publishing - April 4, 2016
No of Pages – 173
Single User PDF License – $3500
Corporate License – $10500
Buy Now - http://www.marketreportsworld.com/purchase/10157403
About Market Reports World: Market Reports World is the credible source for gaining the market
research reports that will exponentially accelerate your business. We are among the leading report
resellers in the business world committed towards optimizing your business. The reports we provide
are based on a research that covers a magnitude of factors such as technological evolution, economic
shifts and a detailed study of market segments.
Contact–
Mr. Ameya Pingaley
Market Reports World
+1-408 520 9750
Email – [email protected]
www.marketreportsworld.com
Powered by TC PDF ( www.tc pdf.orPower ed by TCPDF ( www.tc pdf.orgg) )